DEA and HHS Extend Telemedicine Flexibilities for Controlled Substance Prescriptions Through 2025

The U.S. Drug Enforcement Administration (DEA) and Department of Health and Human Services (HHS) have announced a third extension of telemedicine flexibilities for prescribing Schedule II-V controlled substances. Effective January 1, 2025, healthcare providers can continue prescribing these medications via telemedicine without requiring in-person evaluations until December 31, 2025. This measure is codified by amending 21 C.F.R. § 1307.41 and ensures continuity in patient care while long-term regulatory frameworks are developed.

This extension provides much-needed stability for patients and providers who rely on telemedicine for controlled substance prescriptions.

Key Requirements Under the Extension

To continue utilizing telemedicine for prescribing controlled substances, providers must meet the following conditions:

1. Legitimate Medical Purpose Prescriptions must be issued for valid medical reasons, in alignment with the ordinary course of professional practice.

2. Interactive Telecommunications Systems Audio-visual communication is required for consultations, except in specific cases, such as treating mental health disorders in patients at home, where audio-only communication may suffice.

3. Authorized or Exempted Physicians Prescribers must either hold the appropriate DEA registration to prescribe controlled substances or qualify for an exemption under 21 U.S.C. § 822(d).

4. Regulatory Compliance All prescriptions must comply with the standards outlined in 21 C.F.R. Part 1306, which governs the proper prescribing and dispensing of controlled substances.

The History and Rationale Behind the Extensions

The telemedicine flexibilities originated in March 2020 as a response to the COVID-19 pandemic, which highlighted the limitations of in-person consultations during a public health crisis. Before this, the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 mandated that practitioners conduct in-person evaluations before prescribing controlled substances to prevent misuse and abuse.

During the pandemic, the DEA and HHS leveraged an exception within the Act to allow telemedicine prescribing of controlled substances. This ensured uninterrupted care for patients who could not attend in-person appointments and supported healthcare facilities managing an overwhelming volume of emergency cases.

Since then, the Agencies have twice extended these flexibilities, with the current extension providing time for the development of a final, permanent regulatory solution.

Why the Extension Matters

The Third Temporary Rule aims to:

Maintain continuity for patients who depend on telemedicine relationships established under previous flexibilities.

Avoid overwhelming healthcare providers with a backlog of in-person evaluations.

Provide regulators and stakeholders sufficient time to align with forthcoming permanent regulations.

This extension also reflects a broader recognition of the critical role telemedicine plays in modern healthcare, particularly in enhancing accessibility to medication management services.

The Impact on Digital Health and Telemedicine

The rise of telemedicine platforms since 2020 has reshaped the healthcare landscape. Many digital health companies have integrated telemedicine into their core business models, relying on the extended flexibilities for prescribing controlled substances.

While the extension offers temporary relief, companies must prepare for potential changes in the regulatory environment. The federal government’s approach to telehealth prescribing under a new administration in 2025 could significantly influence the future of digital health services.

Providers and digital health organizations should:

Monitor regulatory developments closely to stay compliant.

Invest in robust compliance frameworks for prescribing practices.

Evaluate their reliance on telemedicine flexibilities and explore contingency plans.

Looking Ahead

As the DEA and HHS work toward finalizing permanent regulations, the telemedicine landscape remains dynamic. Healthcare providers and digital health platforms must remain vigilant, ensuring compliance with current requirements while preparing for future changes.

For more updates on telemedicine regulations and compliance strategies, explore our Insights Section.

MZLS boasts a dedicated team of attorneys licensed to practice in Puerto Rico, Virginia, and Washington, D.C., with extensive experience in navigating federal regulations and compliance. Whether addressing healthcare law, government contracting, or complex legal frameworks, our firm provides comprehensive solutions tailored to your needs. Contact us today to schedule a consultation